[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100645340":3},{"organization":4,"outcomesModule":7,"designInfo":14,"detailedDescription":23,"studyPopulation":13,"armGroups":24,"interventions":37,"overallOfficials":46,"centralContacts":50,"locations":56,"responsibleParty":72,"collaborators":13,"id":76,"slug":77,"hasResults":78,"nctId":79,"briefTitle":80,"officialTitle":81,"acronym":13,"eligibilityCriteria":82,"healthyVolunteers":83,"sex":84,"minAge":85,"maxAge":86,"enrollmentInfo":87,"targetDuration":13,"studyType":90,"phases":91,"briefSummary":93,"conditions":94,"keywords":96,"overallStatus":102,"whyStopped":13,"lastUpdateSubmitDate":103,"lastUpdatePostDateStruct":104,"startDateStruct":107,"completionDateStruct":109,"leadSponsor":111,"locationsCount":112},{"fullName":5,"class":6},"University of Baghdad","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":13},[9],{"measure":10,"description":11,"timeFrame":12},"Changes in Gingival Thickness & Keratinized Tissue Width at baseline and at 6 months after the injection of C-PRF\u002F Hyaluronic acid","Using Trans-ginval probing method to measure the gingival thickness and using Periodontal probe with 1 mm markings to measure the keratinzed tissue width, we measure the difference between the baseline and 6 month after the injection of C-PRF\u002F Hyaluronic acid and compare the readings with the other side that would be injected with C-PRF alone. (To make the assessments repeatable, we will fabricated a stent for each participant. Each stent has a specific hole to measure the gingival thickness through it in order to make the readings as accurate as possible and all the measurements will be in mm scale).","baseline - 6 months follow up",null,{"allocation":15,"interventionModel":16,"interventionModelDescription":13,"primaryPurpose":17,"observationalModel":13,"timePerspective":13,"maskingInfo":18},"RANDOMIZED","SINGLE_GROUP","TREATMENT",{"masking":19,"maskingDescription":13,"whoMasked":20},"DOUBLE",[21,22],"PARTICIPANT","OUTCOMES_ASSESSOR","Gingival phenotype is an important periodontal parameter focused on the gingival thickness and keratinized tissue width.\n\nThe gingival phenotype is either thin or thick. Thick gingival phenotype resist infections and periodontal disease more than the thin gingival phenotype.\n\nMultiple surgical approaches to modify the ginigval phenotype from thin to thick has been done in clinical dentistry.\n\nWhile surgical approach is invasive, recent periodontal trends tends to go with non-invasive ways to treat periodontal conditions. It involves PRF injections as an example.\n\nIn this study we're utilizing the PRF combination with Hyaluronic acid and inject this combination to increase the gingival thickness and keratinized tissue width.",[25,31],{"label":26,"type":27,"description":28,"interventionNames":29},"C-PRF only","ACTIVE_COMPARATOR","In this group, the participants gingival tissue would be injected with C-PRF only, at a fixed point 1.5mm bellow the free gingival margin. (Using the prefabricated stent, the injection would be repeatable each session).",[30],"Other: C-PRF",{"label":32,"type":33,"description":34,"interventionNames":35},"C-PRF\u002F Hyaluronic acid combination","EXPERIMENTAL","In this group, the participants gingival tissue would be injected with C-PRF\u002F Hyaluronic acid combination at a fixed point 1.5mm bellow the free gingival margin. (Using the prefabricated stent, the injection would be repeatable each session).",[36],"Other: C-PRF and Hyaluronic Acid",[38,42],{"type":6,"name":39,"description":40,"armGroupLabels":41,"otherNames":13},"C-PRF and Hyaluronic Acid","A mixed preparation consisting of 0.5 mL of Concentrated Platelet-Rich Fibrin (C-PRF) and 0.5 mL of 1.6% cross-linked hyaluronic acid, 0.2% natural Hyaluronic Acid. The mixture is administered via direct subepithelial injection at the mucogingival junction of the target teeth using a 30-gauge needle. 3 injections sessions with 10 days intervals and baseline, 3 months and 6 months follow up visits.",[32],{"type":6,"name":43,"description":44,"armGroupLabels":45,"otherNames":13},"C-PRF","1 mL of Concentrated Platelet-Rich Fibrin (C-PRF) is administered via direct subepithelial injection at the mucogingival junction of the target teeth using a 30-gauge needle. 3 injections sessions with 10 days intervals and baseline, 3 months and 6 months follow up visits.",[26],[47],{"name":48,"affiliation":13,"role":49},"Sajjad Ahmed Shakir, M.Sc.","PRINCIPAL_INVESTIGATOR",[51],{"name":48,"role":52,"phone":53,"phoneExt":54,"email":55},"CONTACT","07730642935","+964","sajjad.shakir1959@gmail.com",[57],{"facility":58,"status":13,"city":59,"state":60,"zip":61,"country":62,"countryCode":63,"cosmosGeoPoint":64,"geoPoint":69,"contacts":70},"Al-mustansiriyah university","Baghdad","Alresafa","10011","Iraq","IQ",{"type":65,"coordinates":66},"Point",[67,68],44.40088,33.34058,{"lat":68,"lon":67},[71],{"name":48,"role":52,"phone":53,"phoneExt":54,"email":55},{"type":73,"investigatorFullName":74,"investigatorTitle":75,"investigatorAffiliation":5,"oldNameTitle":13,"oldOrganization":13},"SPONSOR_INVESTIGATOR","Sajjad Ahmed Shakir","Master of Science in Periodontics","100645340","super-putty-c-prf-hyaluronic-acid-combination-vs-c-prf-in-gingival-phenotype-modification-in-subjects-with-thin-gingival-phenotype-100645340",false,"NCT07682259","Super Putty C-PRF\u002F Hyaluronic Acid Combination vs C-PRF in Gingival Phenotype Modification in Subjects With Thin Gingival Phenotype","Gingival Phenotype Modification Using Super-putty C-PRF\u002FHyaluronic Acid Combination Versus C-PRF Alone in Subjects With Thin Gingival Phenotype: Randomized Clinical Trials","Inclusion Criteria:\n\n1. Systemically healthy male or female adults aged 20 to 40 years.\n2. Non-smoker.\n3. Presence of a clinically thin gingival phenotype (gingival thickness ≤ 1.0 mm) at the targeted surgical sites.\n4. Presence of bilateral homologous teeth (e.g., both maxillary canines, or both mandibular first premolars) exhibiting the same thin gingival phenotype to allow for paired test and control sites within the same oral cavity.\n5. Patients must demonstrate a high standard of oral hygiene, defined as a full-mouth plaque score and full-mouth bleeding score of ≤ 10% following initial cause-related therapy.\n6. Willingness to comply with the 6-month follow-up schedule and provide written informed consent before enrollment.\n\nExclusion Criteria:\n\n1. Any systemic disease or condition known to compromise wound healing or alter immune response (e.g., uncontrolled diabetes mellitus, autoimmune disorders, bleeding dyscrasias).\n2. Current or recent use of medications known to induce gingival enlargement (e.g., phenytoin, cyclosporine, calcium channel blockers) or medications affecting blood coagulation and platelet function (e.g., anticoagulants) within last 10 days of the procedure.\n3. Active periodontitis, defined by probing depths \\> 3 mm or bleeding on probing at the designated experimental sites\n4. Any previous history of mucogingival surgery, soft tissue grafting, or local trauma at the selected test or control sites.\n5. Current tobacco smoking or vaping, due to its well-documented detrimental effects on local angiogenesis and soft tissue grafting outcomes.\n6. Pregnant or lactating females, due to hormonal fluctuations that can temporarily alter the gingival tissue response and capillary permeability.",true,"ALL","20 Years","40 Years",{"count":88,"type":89},20,"ESTIMATED","INTERVENTIONAL",[92],"NA","Randomized split mouth clinical trials study focused on comparing the efficacy of C-PRF\u002F Hyaluronic acid combination versus C-PRF injection alone in subjects with thin gingival phenotype.",[95],"Thin Gingival Phenotype",[97,98,99,100,101],"periodontics","periodontal phenotype","gingival phenotype","PRF","Hyaluronic acid","NOT_YET_RECRUITING","2026-06-26",{"date":105,"type":106},"2026-07-02","ACTUAL",{"date":108,"type":89},"2026-07-01",{"date":110,"type":89},"2027-08-01",{"name":74,"class":6},1]